Replies to post #198660 on Biotech Values

[willyw]

In geno 3

Sovaldi and daclatasvir; roughly 90% SVR rate

I don't have all the GS-5816 data, but
G-3 in this trial yielded 93% SVR

http://www.hivandhepatitis.com/hcv-treatment/experimental-hcv-drugs/4639-easl-2014-sofosbuvir-gs-5816-inhibitor-is-effective-against-hcv-genotypes-1-6

Gild Astral 3 yielded a 95% SVR rate in G-3............Possibly their best case scenario w/ G-3

http://www.gilead.com/news/press-releases/2015/9/gilead-announces-svr12-rates-from-four-phase-3-studies-evaluating-a-oncedaily-fixeddose-combination-of-sofosbuvir-sof-and-velpatasvir-vel-gs5816-for-the-treatment-of-all-six-hepatitis-c-genotypes

ABT-493 and ABT-530 yielded a 93 and 94% SVR range, so very comparable to SOV/VEL (GS-5816)

I have to wonder if it is possible that in G-3, could Abbvie best or tie the current (SOV/DAC) and soon to be approved G-3 (Sov/Vel) treatments?

Based on these two posted trials the two programs look close in efficacy, but the differences will be better seen when there are more participants and better defined sub groups. (such as cirrhotics and past TX failures)

Abbvie could challenge the status quo; the notion that a nuke is necessary, and that the best G-3 treatment must be Sovaldi based.